Tech Company Financing Transactions
Hubble Therapeutics Funding Round
Hubble Therapeutics closed a $7.3 million Series A financing round on 3/25/2025. Investors included private investors.
Transaction Overview
Company Name
Announced On
3/25/2025
Transaction Type
Venture Equity
Amount
$7,300,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead candidate, HUB-101, into human clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
35 S. Main St
Hanover, NH 03755
USA
Hanover, NH 03755
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
At Hubble Therapeutics, we're driven by a shared vision: restoring sight and transforming lives in patients suffering from LCA16. Meet the passionate team behind our groundbreaking work in gene therapy for LCA16. Together, we're shaping a brighter future, one breakthrough at a time.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
President
Jeff Sabados
Browse more venture capital transactions:
Prev: 3/25/2025: Apricus Generation venture capital transaction
Next: 3/25/2025: Fleetio venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs